Introduction
Progressive fibro-proliferative diseases (FPDs), such as liver cirrhosis, pulmonary fibrosis, scleroderma, ankylosing spondylitis and rheumatoid arthritis, exhibit excessive production of connective tissue and the resulting destruction of normal tissue architecture and function. It is generally recognized that most treatments for these diseases have little effect upon the inexorable pathological progression. Elimination of the initiating cause, where it is known, can be helpful. For example, abstinence from alcohol improves survival in liver cirrhosis [ 13 and removal of patients with early silicosis of the lungs from the silica-dust-laden environment has long been known to be of major benefit. In cases of liver fibrosis resulting from chronic infection with hepatitis C, suppression of viral activity by interferon-a appears to slow the fibrogenic process in a proportion of patients [2] . In most FPDs a chronic inflammatory process may provide a continuing stimulus to fibrogenesis. Treatment of alcoholic liver disease with anti-inflammatory steroids benefits some patients [ 11 and this form of treatment is occasionally dramatically successful for scleroderma and pulmonary fibrosis [ 31. Anti-inflammatory therapy of joint disease generally provides only symptomatic relief.
The possibility of a direct attack on the growth and proliferation of the connective tissue has been raised many times. Cytotoxic drugs have been used in pulmonary fibrosis in the hope of slowing the proliferation of fibroblasts [4] . These drugs are also used in the treatment of rheumatoid arthritis, and methotrexate, for example, shows particular promise although its mode of action is uncertain and may involve suppression of some aspects of immune function [S] . There is increasing interest in the possibility of modulating the functions of cytokines, believed to regulate the proliferative and biosynthetic activities of connective tissue [6] . These include transforming growth factor (TGF)-P, platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and interieukin-1. However, there are formidable technical obstacles to be overcome in the design and development of Abbreviations used: FPD, fibro-proliferative disease; ECM, extracellular matrix. therapeutically useful antagonists of cytokine function.
Attempts have been made at the direct control of collagen synthesis and secretion since excessive accumulation of collagen types I and III is prominent in all FPDs. Cdchicine, which slows the secretion of collagen into the extracellular matrix (ECM), has been used with some apparent success in extended clinical trials to limit the fibrotic process in liver cirrhosis [7] . In experimental models of fibrosis, compounds such as p-aminoproprionitrile, an inhibitor of the collagen cross-linking enzyme, lysyl oxidase EC 1.4.3.14, and various analogues of proline, including 3,4-dehydroproline and cishydroxyproline, all depress the accumulation of collagen [ 81. Unfortunately, these anti-collagen compounds are insufficiently specific to permit sustained clinical use in human fibrotic disease. A more specific agent is therefore required.
Inhibition of prdyl 4-hydroxylase
We have concentrated on the design of inhibitors of prolyl 4-hydroxylase EC 1.14.1 1.2. The activity of his enzyme is essential for the formation of the triple helices of collagen and its subsequent secretion into the ECM [9] . Prolyl 4-hydroxylase belongs to a family of Fez+ -dependent di-oxygenases which couple the oxidative decarboxylation of 2-oxoglutarate to the hydroxylation of the primary substrate. In the case of prolyl 4-hydroxylase the targets of hydroxylation are prolyl residues in the sequence context -X-Pro-Gly-in protocollagen chains. The di-oxygenases use molecular oxygen as the third substrate and require ascorbate as a cofactor.
Consideration of the likely catalytic mechanism of prolyl Chydroxylase [ 101 suggests several possible approaches to the design of inhibitors: (1) Competition with protocollagen The low K , for protocollagen (0.2 p~) indicated that this would be a difficult undertaking, probably requiring a modified oligopeptide to achieve a useful level of competition. reduced activity and the S-enantiomer was markedly more inhibitory than the R-form (Table 1) .
Replacement of the oxalyl C-group with the heterocyclic cinnoline moiety (compound A, Table 1) resulted in a striking increase in inhibitory potency.
Kinetic analysis of compound A showed it to be a potent competitive inhibitor of 2-oxoglutarate with a Ki of 5.1 nM. The stereochemical restriction at the a-carbon atom was similar to that of oxalylglycine itself since the S-form of the methyl derivative (compound A l ) was considerably more active than the R-form, compound A2. Other substitutions at the oxalyl C-group did not improve inhibitory potency.
We think it possible that the heterocyclic derivatives of N-oxalylglycine (heterocyclic carbonylglycines) may co-ordinate the postulated Fez+ at the active centre of the enzyme through the nitrogen atom of the heterocyclic ring ortho to the side-chain and through the amide carbonyl group (Fig. 1) . A free C-group is also necessary for inhibition (data not shown) and this may interact with a complementary positively charged amino-acid sidechain in the enzyme.
Inhibition of collagen hydroxylation in intact cells
The ability of oxalylglycine and its derivatives to inhibit the 4-hydroxylation of collagenous prolyl residues in isolated embryonic-chick-tendon cells was assessed as previously described [ 151. Oxalyl- 
4-hydroxylase
Fe(ll) represents the postulated ferrous ion at the active centre interacting with both the inhibitor and ligands L, and L, provided by amino-acid side-chains in the enzyme 'L, represents a postulated positively charged amino-acid side-chain binding t o the negatively charged C-group of the inhibitor glycine had no effect at concentrations up to 150 p~. Furthermore the cinnoline derivative, compound A, also failed to inhibit at the highest concentration tested, 81 p~, despite its much greater potency against isolated prolyl 4-hydroxylase ( Table 1) . We concluded that the physical properties of both compounds limited their access to the intracellular site of the enzyme. Compounds C and D, in which the cinnoline moiety is replaced by the more lipophilic isoquinoline function, showed more promising activity against intracellular hydroxylation although both compounds were less active against the isolated enzyme (Table 1) . Neither compound C nor D had any effect on the viability of the tendon cells ( -95%), as indicated by the uptake of Trypan Blue, or on the incorporation of ["Clproline into collagen and total cell protein (data not shown).
Inhibition of prolyl 4-hydroxylase activity in vivo
The ability of compounds to inhibit the enzyme in vivo in the rat was assessed as previously described [ 161. Compounds were given orally 2 h before the administration of [ l"C]proline and the animals were killed 2 h after the radiolabel. Table 2 shows that oxyalylglycine (200 mg/kg of body weight) had no effect on the 4-hydroxylation of prolyl residues in the uterine gelatin fraction. Of the heterocylic carbonylglycines tested compound A was inactive, while both C and 1) gave significant inhibition. Compound D was by far the more active and significant inhibition was observed after a dose of 25 mg/kg. Furthermore, inhibition was evident for at least 24 h after a single oral dose of 100 mg/kg. We believe that the marked difference in the activities in vivo of compounds C and I) may be due to the protection against possible metabolic inactivation afforded by the 7-bromo function although this remains to be established directly. Table 2 Although the further development of compound E was precluded by toxicity, apparently unrelated to the inhibition of prolyl .l-hydroxylase, we believe that inhibitors of this enzyme which are free of non-specific toxicity may have potential for the treatment of life-threatening and disabling diseases characterized by the pathological deposition of collagenous ECM.
Inhibition of collagen accumulation in vivo

